Anti-Lipoteichoic acid [BSYX-A110 (Pagibaximab)]

Absolute Antibody

Anti-Lipoteichoic acid [BSYX-A110 (Pagibaximab)]

9

This antibody targets the lipoteichoic acid (LTA) which is a major cell wall component of gram positive bacteria. LTA plays an important role in the initiation and progression of bacterial infection, inflammation, and septic shock. This antibody is also r

This antibody is also known as PMAB, A110 and Hu96-110. This humanized chimeric antibody is derived from murine antibody M110 and is reported to bind whole bacteria and enhance phagocytosis and killing of the bacteria in vitro and enhance protection from lethal infection in vivo. It was originally developed for the prevention of staphylococcal sepsis in infants with low body weight. The serum half-life of the antibody for VLBW infants was 20.5 +/- 6.8 days. Pagibaximab enhanced serum opsonophagocytic activity in infants with no signs of immunogenecity of pagibaximab. All staphylococci causing sepsis were opsonizable by pagibaximab (PMID:19380597). Another study reported that three once-a-week 90 or 60 mg/kg pagibaximab infusions, in high-risk neonates, seemed safe and well tolerated (PMID: 21788224). The binding activity of the antibody to bacteria was determined using whole cell ELISA. The opsonic activity of the antibody was tested with a neutrophil mediated bacteriocidal assay. This Mab enhanced phagocytosis of both coagulase negative and positive Staphylococcus and was reported to enhance survival in both of these types of staphylococcal infections. The results of an initial study suggests that pagibaximab at 3 and 10 mg/kg administered as a single intravenous dose in healthy adults appears to: 1) provide preliminary safety and tolerability data, 2) produce dose-related serum anti-LTA and opsonophagocytic activity levels, 3) have a half-life similar to other immunoglobulin G1 antibodies, 4) exhibit statistically significant correlation between serum anti-LTA and opsonophagocytic activity levels (PMID:19268719). This antibody was also used in combination with lysostaphin and formulated as cream and polymer delivery systems to eradicate the nasal colonization of S. aureus and reduce the risk of nosocomial and community acquired infections (PMID:15553221).

ELISA

Research Use Only

Monoclonal

BSYX-A110 (Pagibaximab)

Human

IgG1

This chimeric human antibody was made using the variable domain sequences of the original Mouse IgG1 format, for improved compatibility with existing reagents, assays and techniques.

Bacteria

-20°C,2°C to 8°C

12352203